Roivant Sciences United States — Net operating losses increased by 298.9% to $890.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 298.9%, from $223.30M to $890.70M.
roiv_segment_united_states_net_operating_losses| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $244.10M | $231.10M | $139.70M | $223.30M | $890.70M |
| QoQ Change | — | -5.3% | -39.5% | +59.8% | +298.9% |
| YoY Change | — | -5.3% | -39.5% | +59.8% | +298.9% |